Business Standard

Lupin extends gain into sixth session as Mandideep unit gets EIR from USFDA

The stock of the drug maker has rallied 47 per cent in the past six trading days, and was quoting close to its 52-week high level of Rs 882

Lupin
Premium

Lupin

SI Reporter Mumbai
Shares of Lupin were trading higher for the sixth straight day, up 3.3 per cent to Rs 854, on the BSE on Wednesday in the intra-day deals after the company’s Mandideep Unit II facility received Establishment Inspection Report (EIR) from the US health regulator.
 
The stock of the drug maker has rallied 47 per cent in the past six trading days, and was quoting close to its 52-week high level of Rs 882 touched on May 2, 2019.

"The company has received the Establishment Inspection Report (EIR) after the closure of the US Food and Drug Administration (USFDA) inspection

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in